Top Biological Safety Testing Companies

Global Biological Safety Testing Market size was valued at USD 5.81 Billion in 2024 and is poised to grow from USD 6.49 Billion in 2025 to USD 15.73 Billion by 2033, growing at a CAGR of 11.7% during the forecast period (2026–2033).

These participants are engaging in strategic collaborations with various information technology companies to strengthen their market presence by offering customers improved information management solutions. 'bioMerieux S.A. (France) ', 'Charles River Laboratories International, Inc. (United States) ', 'Eurofins Scientific SE (Luxembourg) ', 'Lonza Group Ltd. (Switzerland) ', 'Merck KGaA (Germany) ', 'Samsung Biologics (South Korea) ', 'Sartorius AG (Germany) ', 'SGS Société Générale de Surveillance SA (Switzerland) ', 'Thermo Fisher Scientific Inc. (United States) ', 'Avance Biosciences (United States) ', 'Promega Corporation (United States) ', 'Toxikon Corporation (United States) ', 'WuXi AppTec (China) ', 'Pace Analytical Services LLC (United States) ', 'Nelson Laboratories, LLC (United States) ', 'BioReliance Corporation (United States) ', 'Microbac Laboratories, Inc. (United States) ', 'Intertek Group plc (United Kingdom) ', 'Covance Inc. (United States)'

In vitro testing methods, such as cell-based assays and immunoassays, are gaining popularity due to their advantages over traditional animal-based testing. These methods provide quicker results, reduce the need for animal testing, and offer cost-efficiency, thereby driving their adoption and fueling market growth.

Growing Focus on Patient Safety: Patient safety has emerged as a critical concern in the healthcare industry, leading to a heightened emphasis on rigorous biological safety testing. The occurrence of adverse events due to contaminated or substandard biological products can have severe consequences for patients. As a result, healthcare providers, regulatory authorities, and manufacturers are prioritizing quality control measures to ensure the safety and well-being of patients. This focus on patient safety drives the demand for comprehensive biological safety testing and promotes market growth.

North America dominates the biological safety testing market, accounting for over of the total revenue. The region's dominance can be attributed to several factors, including a well-established healthcare infrastructure, favorable government initiatives, and a large number of pharmaceutical and biotechnology companies. The United States, in particular, plays a pivotal role in driving market growth, owing to substantial investments in research and development activities. The stringent regulatory framework, enforced by agencies such as the Food and Drug Administration (FDA), further emphasizes the need for comprehensive safety testing, boosting market demand.